[1]
|
McGrogan, A., Sneddon, S. and de Vries, C.S. (2010) The Incidence of Myasthenia Gravis: A Systematic Literature Review. Neuroepidemiology, 34, 171-183. https://doi.org/10.1159/000279334
|
[2]
|
Chen, J., Tian, D.C., Zhang, C., et al. (2020) Incidence, Mortality, and Economic Burden of Myasthenia Gravis in China: A Nationwide Population-Based Study. The Lancet Regional Health. Western Pacific, 5, Article ID: 100063.
https://doi.org/10.1016/j.lanwpc.2020.100063
|
[3]
|
Mantegazza, R., Vanoli, F., Frangiamore, R., et al. (2020) Complement Inhibition for the Treatment of Myasthenia Gravis. ImmunoTargets and Therapy, 9, 317-331. https://doi.org/10.2147/ITT.S261414
|
[4]
|
Narayanaswami, P., Sanders, D.B., Wolfe, G., et al. (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology, 96, 114-122. https://doi.org/10.1212/WNL.0000000000011124
|
[5]
|
Boye, J., Elter, T. and Engert, A. (2003) An Overview of the Current Clinical Use of the Anti-CD20 Monoclonal Antibody Rituximab. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 14, 520-535.
https://doi.org/10.1093/annonc/mdg175
|
[6]
|
Hui-Yuen, J.S., Nguyen, S.C. and Askanase, A.D. (2016) Targeted B Cell Therapies in the Treatment of Adult and Pediatric Systemic Lupus Erythematosus. Lupus, 25, 1086-1096. https://doi.org/10.1177/0961203316652491
|
[7]
|
Einarsson, J.T., Evert, M., Geborek, P., et al. (2017) Rituximab in Clinical Practice: Dosage, Drug Adherence, Ig Levels, Infections, and Drug Antibodies. Clinical Rheumatology, 36, 2743-2750.
https://doi.org/10.1007/s10067-017-3848-6
|
[8]
|
Grace, R.F., Shimano, K.A., Bhat, R., et al. (2019) Second-Line Treatments in Children with Immune Thrombocytopenia: Effect on Platelet Count and Patient-Centered Outcomes. American Journal of Hematology, 94, 741-750.
https://doi.org/10.1002/ajh.25479
|
[9]
|
Ishiura, H., Matsuda, S., Higashihara, M., et al. (2008) Response of Anti-NMDA Receptor Encephalitis without Tumor to Immunotherapy Including Rituximab. Neurology, 71, 1921-1923.
https://doi.org/10.1212/01.wnl.0000336648.43562.59
|
[10]
|
Collongues, N. and de Seze, J. (2016) An Update on the Evidence for the Efficacy and Safety of Rituximab in the Management of Neuromyelitis Optica. Therapeutic Advances in Neurological Disorders, 9, 180-188.
https://doi.org/10.1177/1756285616632653
|
[11]
|
Cragg, M.S., Walshe, C.A., Ivanov, A.O., et al. (2005) The Biology of CD20 and Its Potential as a Target for mAb Therapy. Current Directions in Autoimmunity, 8, 140-174. https://doi.org/10.1159/000082102
|
[12]
|
Niwa, R., Hatanaka, S., Shoji-Hosaka, E., et al. (2004) Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcgammaRIIIa Functional Polymorphism. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10, 6248-6255.
https://doi.org/10.1158/1078-0432.CCR-04-0850
|
[13]
|
Panjideh, H., Müller, G., Koch, M., et al. (2014) Immunotherapy of B-Cell Non-Hodgkin Lymphoma by Targeting the Chemokine Receptor CXCR5 in a Preclinical Mouse Model. International Journal of Cancer, 135, 2623-2632.
https://doi.org/10.1002/ijc.28893
|
[14]
|
Vigna-Perez, M., Hernández-Castro, B., Paredes-Saharopulos, O., et al. (2006) Clinical and Immunological Effects of Rituximab in Patients with Lupus Nephritis Refractory to Conventional Therapy: A Pilot Study. Arthritis Research & Therapy, 8, R83. https://doi.org/10.1186/ar1954
|
[15]
|
Zaja, F., Russo, D., Fuga, G., et al. (2000) Rituximab for Myasthenia Gravis Developing after Bone Marrow Transplant. Neurology, 55, 1062-1063. https://doi.org/10.1212/WNL.55.7.1062-a
|
[16]
|
Collongues, N., Casez, O., Lacour, A., et al. (2012) Rituximab in Refractory and Non-Refractory Myasthenia: A Retrospective Multicenter Study. Muscle & Nerve, 46, 687-691. https://doi.org/10.1002/mus.23412
|
[17]
|
Anderson, D., Phan, C., Johnston, W.S., et al. (2016) Rituximab in Refractory Myasthenia Gravis: A Prospective, Open-Label Study with Long-Term Follow-up. Annals of Clinical and Translational Neurology, 3, 552-555.
https://doi.org/10.1002/acn3.314
|
[18]
|
Brauner, S., Eriksson-Dufva, A., Hietala, M.A., et al. (2020) Comparison between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurology, 77, 974-981. https://doi.org/10.1001/jamaneurol.2020.0851
|
[19]
|
Díaz-Manera, J., Martínez-Hernández, E., Querol, L., et al. (2012) Long-Lasting Treatment Effect of Rituximab in MuSK Myasthenia. Neurology, 78, 189-193. https://doi.org/10.1212/WNL.0b013e3182407982
|
[20]
|
Litchman, T., Roy, B., Kumar, A., et al. (2020) Differential Response to Rituximab in Anti-AChR and Anti-MuSK Positive Myasthenia Gravis Patients: A Single-Center Retrospective Study. Journal of the Neurological Sciences, 411, Article ID: 116690. https://doi.org/10.1016/j.jns.2020.116690
|
[21]
|
Zhang, C., Bu, B., Yang, H., et al. (2020) Immunotherapy Choice and Maintenance for Generalized Myasthenia Gravis in China. CNS Neuroscience & Therapeutics, 26, 1241-1254. https://doi.org/10.1111/cns.13468
|
[22]
|
Tandan, R., Hehir II, M.K., Waheed, W., et al. (2017) Rituximab Treatment of Myasthenia Gravis: A Systematic Review. Muscle & Nerve, 56, 185-196. https://doi.org/10.1002/mus.25597
|